Thorsten Rieckmann
Priv.-Doz. Dr. phil. nat.
Thorsten Rieckmann
  • 1.Arbeitsbereich
Deutsch (Muttersprache)



  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma
Borgmann M, Oetting A, Meyer F, Möckelmann N, Droste C, von Bargen C, Möller-Koop C, Witt M, Borgmann K, Rothkamm K, Betz C, Münscher A, Clauditz T, Rieckmann T
J CANCER RES CLIN. 2023;149(7):3383-3393.

G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells
Cetin M, Rieckmann T, Hoffer K, Riepen B, Christiansen S, Gatzemeier F, Feyerabend S, Schoof M, Schüller U, Petersen C, Mynarek M, Rothkamm K, Kriegs M, Struve N
RADIAT ONCOL. 2023;18(1):.

Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells
Grottker F, Gehre S, Reichardt C, Sengedorj A, Jost T, Rieckmann T, Hecht M, Gostian A, Frey B, Fietkau R, Gaipl U, Rückert M
NEOPLASIA. 2023;45:100944.

Impaired DNA double-strand break repair and effective radiosensitization of HPV-negative HNSCC cell lines through combined inhibition of PARP and Wee1
Oetting A, Christiansen S, Gatzemeier F, Köcher S, Bußmann L, Böttcher A, Stölzel K, Hoffmann A, Struve N, Kriegs M, Petersen C, Betz C, Rothkamm K, Zech H, Rieckmann T
CLIN TRANSL RAD ONCO. 2023;41:100630.

Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy
Viktorsson K, Rieckmann T, Fleischmann M, Diefenhardt M, Hehlgans S, Rödel F
STRAHLENTHER ONKOL. 2023;199(12):1091-1109.

Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib
Vu A, Akingunsade L, Hoffer K, Petersen C, Betz C, Rothkamm K, Rieckmann T, Bussmann L, Kriegs M
HEAD NECK-J SCI SPEC. 2023;45(1):147-155.

Tissue Microarray Analyses Suggest Axl as a Predictive Biomarker in HPV-Negative Head and Neck Cancer
Busch C, Hagel C, Becker B, Oetting A, Möckelmann N, Droste C, Möller-Koop C, Witt M, Blaurock M, Loges S, Rothkamm K, Betz C, Münscher A, Clauditz T, Rieckmann T
CANCERS. 2022;14(7):.

Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology - A proof-of-concept study
Busch C, Hoffmann A, Viarisio D, Becker B, Rieckmann T, Betz C, Bender N, Schroeder L, Hussein Y, Petersen E, Jagodzinski A, Schäfer I, Burandt E, Lang Kuhs K, Pawlita M, Waterboer T, Brenner N

A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells
Köcher S, Zech H, Krug L, Gatzemeier F, Christiansen S, Meyer F, Rietow R, Struve N, Mansour W, Kriegs M, Petersen C, Betz C, Rothkamm K, Rieckmann T
FRONT ONCOL. 2022;12:.

The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey
Krishnamurthy S, Ahmed I, Bhise R, Mohanti B, Sharma A, Rieckmann T, Paterson C, Bonomo P
CLIN TRANSL RAD ONCO. 2022;34:75-81.

Increased replication stress and R-loop accumulation in EGFRvIII expressing glioblastoma present new therapeutic opportunities
Struve N, Hoffer K, Weik A, Riepen B, Krug L, Cetin M, Burmester J, Ott L, Liebing J, Gatzemeier F, Müller-Goebel J, Bußmann L, Parplys A, Unger K, Mansour W, Schüller U, Rieckmann T, Petersen C, Rothkamm K, Short S, Kriegs M
NEURO-ONCOL ADV. 2022;4(1):vdab180.

Head and neck tumor cells treated with hypofractionated irradiation die via apoptosis and are better taken up by M1-like macrophages
Wedekind H, Walz K, Buchbender M, Rieckmann T, Strasser E, Grottker F, Fietkau R, Frey B, Gaipl U, Rückert M
STRAHLENTHER ONKOL. 2022;198(2):171-182.

Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer
Zech H, Berger J, Mansour W, Nordquist L, von Bargen C, Bußmann L, Oetting A, Christiansen S, Möckelmann N, Böttcher A, Busch C, Petersen C, Betz C, Rothkamm K, Kriegs M, Köcher S, Rieckmann T
RADIOTHER ONCOL. 2022;168:138-146.

Kinomic comparison of snap frozen and ex vivo-cultured head and neck tumors
Berger J, Zech H, Hoffer K, von Bargen C, Nordquist L, Bussmann L, Gatzemeier F, Busch C, Möckelmann N, Münscher A, Betz C, Petersen C, Rothkamm K, Rieckmann T, Köcher S, Kriegs M
ORAL ONCOL. 2021;123:.

Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src-family kinases as prognostic markers and potential targets
Bußmann L, Hoffer K, von Bargen C, Droste C, Lange T, Kemmling J, Schröder-Schwarz J, Vu A, Akingunsade L, Nollau P, Rangarajan S, de Wijn R, Oetting A, Müller C, Böckelmann L, Zech H, Berger J, Möckelmann N, Busch C, Böttcher A, Gatzemeier F, Klinghammer K, Simnica D, Binder M, Struve N, Rieckmann T, Schumacher U, Clauditz T, Betz C, Petersen C, Rothkamm K, Münscher A, Kriegs M
INT J CANCER. 2021;149(5):1166 - 1180.

Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells
Hintelmann K, Berenz T, Kriegs M, Christiansen S, Gatzemeier F, Struve N, Petersen C, Betz C, Rothkamm K, Oetting A, Rieckmann T
FRONT ONCOL. 2021;11:683688.

Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting
Hintelmann K, Kriegs M, Rothkamm K, Rieckmann T
FRONT ONCOL. 2020;10:1260.

Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays
Rothkamm K, Christiansen S, Rieckmann T, Horn M, Frenzel T, Brinker A, Schumacher U, Stein A, Petersen C, Burdak-Rothkamm S
CANCER LETT. 2020;493:179-188.

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining
Schötz U, Balzer V, Brandt F, Ziemann F, Subtil F, Rieckmann T, Köcher S, Engenhart-Cabillic R, Dikomey E, Wittig A, Arenz A
CANCERS. 2020;12(2):.

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
Struve N, Binder Z, Stead L, Brend T, Bagley S, Faulkner C, Ott L, Müller-Goebel J, Weik A, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette J, Kurian K, Schüller U, Petersen C, Rothkamm K, O Rourke D, Short S, Kriegs M
ONCOGENE. 2020;39(15):3041-3055.

Mass Spectrometric Comparison of HPV-Positive and HPV-Negative Oropharyngeal Cancer
Wurlitzer M, Möckelmann N, Kriegs M, Vens M, Omidi M, Hoffer K, Bargen C, Möller-Koop C, Witt M, Droste C, Oetting A, Petersen H, Busch C, Münscher A, Schlüter H, Clauditz T, Rieckmann T
CANCERS. 2020;12(6):.

Analyzing expression and phosphorylation of the EGF receptor in HNSCC
Kriegs M, Clauditz T, Hoffer K, Bartels J, Buhs S, Gerull H, Zech H, Bußmann L, Struve N, Rieckmann T, Petersen C, Betz C, Rothkamm K, Nollau P, Münscher A
SCI REP-UK. 2019;9(1):13564.

The inflammation-reducing compatible solute ectoine does not impair the cytotoxic effect of ionizing radiation on head and neck cancer cells
Rieckmann T, Gatzemeier F, Christiansen S, Rothkamm K, Münscher A
SCI REP-UK. 2019;9(1):6594.

The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective
Rieckmann T, Kriegs M
CLIN TRANSL RAD ONCO. 2019;17:47-50.

Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy.
Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Rieckmann T, Falk S, Rödel C, Fokas E
BBA-REV CANCER. 2019;1871(1):126-137.

Current studies of immunotherapy in head and neck cancer
Dogan V, Rieckmann T, Münscher A, Busch C
CLIN OTOLARYNGOL. 2018;43(1):13-21.

G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1
Busch C, Kröger M, Jensen J, Kriegs M, Gatzemeier F, Petersen C, Münscher A, Rothkamm K, Rieckmann T
RADIOTHER ONCOL. 2017;122(2):260-266.

Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines
Ziemann F, Seltzsam S, Dreffke K, Preising S, Arenz A, Subtil F, Rieckmann T, Engenhart-Cabillic R, Dikomey E, Wittig A
ONCOTARGET. 2017;8(62):105170-105183.

DNA Repair
Borgmann K, Köcher S, Kriegs M, Mansour Khalfallah W, Parplys A, Rieckmann T, Rothkamm K
2016. Molecular Radio-Oncology. Baumann M, Krause M, Cordes N (Hrsg.). 1. Aufl. Berlin Heidelberg: Springer, 1-24.

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
Busch C, Becker B, Kriegs M, Gatzemeier F, Krüger K, Möckelmann N, Fritz G, Petersen C, Knecht R, Rothkamm K, Rieckmann T
ONCOTARGET. 2016;7(24):35832-35842.

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer
Bussmann L, Busch C, Lörincz B, Rieckmann T, Block A, Knecht R
EUR ARCH OTO-RHINO-L. 2016;273(12):4073-4080.

Radiation DNA damage and use in cancer/therapeutics-translation of radiation modifiers
Dikomey E, Borgmann K, Köcher S, Kriegs M, Mansour Khalfallah W, Parplys A, Rieckmann T, Rothkamm K
2016. DNA Repair in Cancer Therapy. Kelley M, Fishel M (Hrsg.). 2. Aufl. London: Elsevier Science, 329 - 352.

DNA repair after oncological therapy (radiotherapy and chemotherapy)
Dikomey E, Borgmann K, Kriegs M, Mansour Khalfallah W, Petersen C, Rieckmann T
2016. Oxford Textbook of Oncology. Kerr D, Haller D, van de Velde C, Baumann M (Hrsg.). 3. Aufl. Oxford: Oxford University Press, 82-85.

Targeted nanoparticles for tumour radiotherapy enhancement - the long dawn of a golden era?
Gargioni E, Schulz F, Raabe A, Burdak-Rothkamm S, Rieckmann T, Rothkamm K
ANN TRANSL MED. 2016;4(24):523.

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K
ONCOTARGET. 2016;7(29):45122-45133.

Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries: Results from a web-based survey of the Young DEGRO working group
Krug D, Baumann R, Rieckmann T, Fokas E, Gauer T, Niyazi M
STRAHLENTHER ONKOL. 2016;192(8):507-15.

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
Möckelmann N, Rieckmann T, Busch C, Becker B, Gleißner L, Hoffer K, Omniczynski M, Steinmeister L, Laban S, Grénman R, Petersen C, Rothkamm K, Dikomey E, Knecht R, Kriegs M
ONCOTARGET. 2016;7(17):23542-51.

HPV and Radiation Sensitivity
De Costa A, Rieckmann T, Kimple R
2015. Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer. Miller D, Stack M (Hrsg.). 1. Aufl. Springer, 243-289.

Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest
Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob T, Laban S, Kasten-Pisula U, Petersen C, Baumann M, Krause M, Dikomey E
RADIOTHER ONCOL. 2015;115(1):120-7.

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
Struve N, Riedel M, Schulte A, Rieckmann T, Grob T, Gal A, Rothkamm K, Lamszus K, Petersen C, Dikomey E, Kriegs M
ONCOTARGET. 2015;6(32):33867-77.

The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines
Güster J, Weissleder S, Busch C, Kriegs M, Petersen C, Knecht R, Dikomey E, Rieckmann T
RADIOTHER ONCOL. 2014;113(3):345-51.

HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1
Busch C, Kriegs M, Laban S, Tribius S, Knecht R, Petersen C, Dikomey E, Rieckmann T
RADIOTHER ONCOL. 2013;108(3):495-9.

Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma.
Mansour Khalfallah W, Bogdanova N, Kasten-Pisula U, Rieckmann T, Köcher S, Borgmann K, Baumann M, Krause M, Petersen C, Hu H, Gatti R, Dikomey E, Dörk T, Dahm-Daphi J
RADIOTHER ONCOL. 2013;106(1):147-154.

p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation.
Rieckmann T, Kriegs M, Nitsch L, Hoffer K, Rohaly G, Köcher S, Petersen C, Dikomey E, Dornreiter I, Dahm-Daphi J
ONCOGENE. 2013;32(8):968-975.

HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
Rieckmann T, Tribius S, Grob T, Meyer F, Busch C, Petersen C, Dikomey E, Kriegs M
RADIOTHER ONCOL. 2013;107(2):242-246.

Radiation-induced double-strand breaks require ATM but not Artemis for homologous recombination during S-phase.
Köcher S, Rieckmann T, Rohaly G, Mansour W, Dikomey E, Dornreiter I, Dahm-Daphi J
NUCLEIC ACIDS RES. 2012;40(17):8336-8347.

In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status.
Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E, Kriegs M
RADIOTHER ONCOL. 2011;101(1):147-151.

Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.
Tribius S, Ihloff A, Rieckmann T, Petersen C, Hoffmann M
CANCER LETT. 2011;304(2):71-79.

The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J, Dikomey E
DNA REPAIR. 2010;9(8):889-897.

Rapid fusion and syncytium formation of heterologous cells upon expression of the FGFRL1 receptor.
Steinberg F, Gerber S, Rieckmann T, Trueb B
J BIOL CHEM. 2010;285(48):37704-37715.

Letzte Aktualisierung aus dem FIS: 19.06.2024 - 00:47 Uhr